Amylose resistant starch (HAM-RS2) supplementation increases the proportion of Faecalibacterium bacteria in end-stage renal disease patients: Microbial analysis from a randomized placebo-controlled trial.
Michael R LaffinHamid Tayebi KhosroshahiHeekuk ParkLuke J LaffinKaren MadsenHossein Samadi KafilBehzad AbediSomayeh ShiralizadehNosratola D VaziriPublished in: Hemodialysis international. International Symposium on Home Hemodialysis (2019)
Supplementation of amylose resistant starch, HAM-RS2, in patients with CKD led to an elevation in Faecalibacterium and decrease in systemic inflammation. Microbial manipulation in CKD patients by using the prebiotic fiber may exert an anti-inflammatory effect through an elevation in the bacterial genera Faecalibacterium.